South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Purpose: Pirfenidone and nintedanib are two novel antifibrotic agents licensed for the treatment IPF. Prior to being approved for use in England for patients with FVC >50% and <80%, these were made available for all IPF patients under the Mild Patient Program (MPP) and Patient In Need Scheme (...

Descripción completa

Detalles Bibliográficos
Autores principales: Barratt, Shaney L., Mulholland, Sarah, Al Jbour, Khaled, Steer, Henry, Gutsche, Markus, Foley, Noeleen, Srivastava, Rajiv, Sharp, Charles, Adamali, Huzaifa I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304353/
https://www.ncbi.nlm.nih.gov/pubmed/30618768
http://dx.doi.org/10.3389/fphar.2018.01480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304353/
https://www.ncbi.nlm.nih.gov/pubmed/30618768
http://dx.doi.org/10.3389/fphar.2018.01480

Ejemplares similares